Foresters Investment Management Company Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 448,554 shares of the company’s stock after selling 37,050 shares during the quarter. Johnson & Johnson comprises about 1.1% of Foresters Investment Management Company Inc.’s investment portfolio, making the stock its 10th largest position. Foresters Investment Management Company Inc.’s holdings in Johnson & Johnson were worth $57,886,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Evolution Wealth Advisors LLC bought a new position in Johnson & Johnson during the fourth quarter valued at $40,000. Crewe Advisors LLC increased its position in Johnson & Johnson by 75.0% during the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock valued at $45,000 after acquiring an additional 150 shares during the last quarter. Horan Securities Inc. increased its position in Johnson & Johnson by 122.3% during the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after acquiring an additional 241 shares during the last quarter. Stuart Chaussee & Associates Inc. increased its position in Johnson & Johnson by 20.7% during the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 80 shares during the last quarter. Finally, Ruggie Capital Group increased its position in Johnson & Johnson by 342.5% during the fourth quarter. Ruggie Capital Group now owns 469 shares of the company’s stock valued at $60,000 after acquiring an additional 363 shares during the last quarter. 66.90% of the stock is currently owned by institutional investors.

NYSE JNJ opened at $141.68 on Thursday. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $367.86 billion, a PE ratio of 17.32, a P/E/G ratio of 2.39 and a beta of 0.70. Johnson & Johnson has a 12 month low of $120.11 and a 12 month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. The firm had revenue of $20.02 billion for the quarter, compared to analysts’ expectations of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The business’s revenue for the quarter was up .1% on a year-over-year basis. During the same period in the prior year, the business posted $2.06 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 11th. Stockholders of record on Tuesday, May 28th were issued a $0.95 dividend. The ex-dividend date was Friday, May 24th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

A number of research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective on the stock in a research report on Wednesday, March 27th. BMO Capital Markets boosted their price objective on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 17th. Raymond James upped their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Finally, Credit Suisse Group upped their price target on shares of Johnson & Johnson from $152.00 to $156.00 and gave the stock an “outperform” rating in a report on Thursday, May 16th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and a consensus price target of $147.30.

In related news, Director Marillyn A. Hewson purchased 3,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $419,040. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Marea Informative and is the property of of Marea Informative. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.mareainformativa.com/news/2019/06/13/foresters-investment-management-company-inc-decreases-position-in-johnson-johnson-nysejnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Channel Trading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.